(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
An2 Therapeutics's earnings in 2025 is -$45,353,000.On average, 1 Wall Street analyst forecast ANTX's earnings for 2025 to be -$35,607,350, with the lowest ANTX earnings forecast at -$35,607,350, and the highest ANTX earnings forecast at -$35,607,350. On average, 1 Wall Street analyst forecast ANTX's earnings for 2026 to be -$28,968,691, with the lowest ANTX earnings forecast at -$28,968,691, and the highest ANTX earnings forecast at -$28,968,691.
In 2027, ANTX is forecast to generate -$35,305,592 in earnings, with the lowest earnings forecast at -$35,305,592 and the highest earnings forecast at -$35,305,592.